Pliant Therapeutics (PLRX) has released an update.
Pliant Therapeutics Inc. reported positive outcomes from their Phase 2a clinical trial of bexotegrast for primary sclerosing cholangitis, a liver condition. The 320 mg dose group achieved primary and secondary goals, showing good tolerance and dose-responsive plasma concentration without increasing adverse events. Notably, the drug led to reductions in liver fibrosis markers, stabilized liver enzymes, and improved liver function and bile flow in patients, compared to placebo, after 12 weeks of treatment.
For further insights into PLRX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
